Psyence BioMed Chief of Global Impact to speak at Psychedelic Science 2025Psyence Group2025-06-18T14:37:22+02:00June 18, 2025|Read More
Psyence BioMed Regains Full Compliance with Nasdaq Continued Listing RequirementsPsyence Group2025-06-17T09:38:38+02:00June 17, 2025|Read More
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical TrialPsyence Group2025-05-27T14:44:03+02:00May 27, 2025|Read More
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyPsyence Group2025-04-21T08:16:12+02:00April 21, 2025|Read More
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply AgreementPsyence Group2025-04-15T14:50:08+02:00April 15, 2025|Read More
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in AustraliaPsyence Group2025-04-09T09:40:45+02:00April 9, 2025|Read More
Psyence Biomedical LTD Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable ManufacturingPsyence Group2025-03-31T14:48:31+02:00March 31, 2025|Read More
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. SteinPsyence Group2025-03-19T14:36:13+02:00March 19, 2025|Read More
